HR Execs on the Move


 
Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.amylyx.com
  • 43 Thorndike Street
    Cambridge, MA USA 02141
  • Phone: 617.682.0917

Executives

Name Title Contact Details
Martin Mitchell
Head of Global Talent Attraction Profile
Doreen Nichols
Head of Talent and HR Business Partnering Profile
Linda Arsenault
Chief Human Resources Officer Profile

Similar Companies

Diva Pharmaceuticals

Diva Pharmaceuticals is a Upper Saddle River, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pliant Therapeutics

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant`s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

Orascoptic

Orascoptic offers award-winning, custom-fit dental and surgical loupes and headlights for loupes with a 45-day trial period.

Sirnaomics

Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology.